We selected markers available from the translational program of the AVETUX trial like Tumor infiltrating lymphocyte (TiL), myeloid cell and NK cell frequencies; tumor mass calculated at baseline in CT scans; TiL and peripheral blood mononuclear cell (PBMC) clonality and diversity and PD-L1 expression measured as IC score. Here, CD274 is linked to neoplasm.